Key Drivers of HTA Decisions for "Life-Changing" Drugs

There are mechanisms in place to reward innovative and “life-changing” drugs. Most of these mechanisms exist in the regulatory process, but what about the reimbursement process? Are “life-changing” drugs rewarded by health technology assessment (HTA) agencies with positive reimbursement decisions? This original research applies a data-driven approach to evaluate the key drivers of HTA agency decisions for drugs that provided significant improvement in benefits over existing therapies.

Read the full analysis and conclusions in the research brief.

Original research presented at the ISPOR 19th Annual European Congress 2016 in Vienna


Register to Download Research Brief

Name *
Name
Company Name
Communication Preferences
Thank you for your interest in Context Matters. You will receive future communications. To opt-out, check the box below.